 Sridharan Raghavan
Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 27 | 2025 | 2442 | 3.870 |
Why?
| | Cardiovascular Diseases | 10 | 2025 | 2006 | 1.810 |
Why?
| | Veterans | 8 | 2024 | 1375 | 1.450 |
Why?
| | Blood Glucose | 15 | 2022 | 2100 | 1.300 |
Why?
| | Diabetes Mellitus | 6 | 2023 | 1001 | 1.150 |
Why?
| | Life Style | 3 | 2025 | 461 | 0.890 |
Why?
| | Myocardial Infarction | 4 | 2025 | 1021 | 0.860 |
Why?
| | Dementia, Vascular | 1 | 2022 | 20 | 0.800 |
Why?
| | Machine Learning | 4 | 2022 | 443 | 0.780 |
Why?
| | Metformin | 2 | 2025 | 318 | 0.770 |
Why?
| | Hypertension | 2 | 2022 | 1243 | 0.750 |
Why?
| | Risk Factors | 20 | 2024 | 9786 | 0.710 |
Why?
| | Coronary Artery Disease | 4 | 2022 | 679 | 0.710 |
Why?
| | Alzheimer Disease | 2 | 2023 | 514 | 0.670 |
Why?
| | Hypoglycemic Agents | 5 | 2025 | 1221 | 0.650 |
Why?
| | Early Medical Intervention | 1 | 2019 | 57 | 0.620 |
Why?
| | Genetic Predisposition to Disease | 8 | 2025 | 2274 | 0.620 |
Why?
| | Genetic Counseling | 1 | 2019 | 72 | 0.620 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 430 | 0.580 |
Why?
| | Models, Statistical | 2 | 2021 | 625 | 0.580 |
Why?
| | Fasting | 4 | 2025 | 267 | 0.570 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 198 | 0.570 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 376 | 0.570 |
Why?
| | Secondary Prevention | 1 | 2019 | 219 | 0.570 |
Why?
| | Weight Loss | 2 | 2021 | 738 | 0.560 |
Why?
| | Behavior Therapy | 1 | 2019 | 241 | 0.540 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 321 | 0.530 |
Why?
| | Genome-Wide Association Study | 8 | 2023 | 1326 | 0.510 |
Why?
| | Research Design | 2 | 2021 | 1045 | 0.490 |
Why?
| | Population Surveillance | 1 | 2019 | 439 | 0.490 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 485 | 0.490 |
Why?
| | Risk Assessment | 4 | 2024 | 3262 | 0.440 |
Why?
| | Humans | 46 | 2025 | 129626 | 0.430 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2025 | 2060 | 0.410 |
Why?
| | Incidence | 8 | 2025 | 2641 | 0.410 |
Why?
| | Mycobacterium tuberculosis | 4 | 2008 | 309 | 0.380 |
Why?
| | Social Support | 1 | 2016 | 584 | 0.380 |
Why?
| | Insulin Resistance | 3 | 2021 | 1167 | 0.380 |
Why?
| | Prediabetic State | 2 | 2025 | 244 | 0.370 |
Why?
| | Metabolic Syndrome | 1 | 2015 | 340 | 0.360 |
Why?
| | Aged | 15 | 2025 | 22061 | 0.350 |
Why?
| | Middle Aged | 19 | 2025 | 31136 | 0.340 |
Why?
| | Retrospective Studies | 10 | 2023 | 14522 | 0.340 |
Why?
| | Virulence Factors | 2 | 2008 | 157 | 0.340 |
Why?
| | Adult | 16 | 2025 | 35599 | 0.320 |
Why?
| | Follow-Up Studies | 5 | 2025 | 4894 | 0.300 |
Why?
| | Atherosclerosis | 2 | 2024 | 402 | 0.290 |
Why?
| | Bacterial Proteins | 3 | 2008 | 836 | 0.280 |
Why?
| | Male | 23 | 2025 | 63670 | 0.260 |
Why?
| | United States | 9 | 2025 | 13871 | 0.260 |
Why?
| | Female | 23 | 2025 | 68734 | 0.250 |
Why?
| | Genetic Variation | 2 | 2025 | 939 | 0.250 |
Why?
| | Obesity | 3 | 2022 | 2882 | 0.240 |
Why?
| | Survival Rate | 2 | 2019 | 1872 | 0.220 |
Why?
| | Hyperinsulinism | 1 | 2025 | 119 | 0.220 |
Why?
| | Insulin | 4 | 2025 | 2326 | 0.210 |
Why?
| | Comorbidity | 2 | 2018 | 1547 | 0.200 |
Why?
| | Biguanides | 1 | 2022 | 12 | 0.200 |
Why?
| | Selection Bias | 1 | 2022 | 37 | 0.200 |
Why?
| | Calibration | 1 | 2022 | 140 | 0.190 |
Why?
| | Causality | 1 | 2022 | 117 | 0.190 |
Why?
| | Veterans Health | 2 | 2020 | 177 | 0.190 |
Why?
| | Transcription Factors | 2 | 2016 | 1647 | 0.190 |
Why?
| | Body Height | 1 | 2022 | 192 | 0.190 |
Why?
| | Chromosome Mapping | 1 | 2022 | 505 | 0.180 |
Why?
| | Entropy | 1 | 2021 | 39 | 0.180 |
Why?
| | Coronary Disease | 1 | 2023 | 385 | 0.180 |
Why?
| | Insurance Carriers | 1 | 2021 | 11 | 0.180 |
Why?
| | Cause of Death | 2 | 2022 | 395 | 0.170 |
Why?
| | Probability | 1 | 2021 | 306 | 0.170 |
Why?
| | Colonic Neoplasms | 1 | 2022 | 242 | 0.170 |
Why?
| | Diabetic Retinopathy | 1 | 2022 | 178 | 0.170 |
Why?
| | Insulin-Secreting Cells | 1 | 2024 | 364 | 0.160 |
Why?
| | Precision Medicine | 1 | 2023 | 387 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2720 | 0.160 |
Why?
| | Macrophages | 5 | 2008 | 1488 | 0.160 |
Why?
| | Nutrition Surveys | 1 | 2021 | 260 | 0.160 |
Why?
| | Coronary Artery Bypass | 1 | 2021 | 224 | 0.160 |
Why?
| | Guidelines as Topic | 1 | 2021 | 264 | 0.150 |
Why?
| | Cigarette Smoking | 1 | 2020 | 91 | 0.150 |
Why?
| | Insurance, Health | 1 | 2021 | 267 | 0.150 |
Why?
| | Diabetic Nephropathies | 1 | 2022 | 284 | 0.150 |
Why?
| | Mendelian Randomization Analysis | 3 | 2023 | 47 | 0.150 |
Why?
| | Exercise | 2 | 2021 | 1928 | 0.150 |
Why?
| | Patient Readmission | 1 | 2023 | 653 | 0.150 |
Why?
| | Diabetes Complications | 1 | 2019 | 224 | 0.140 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1005 | 0.140 |
Why?
| | Body Mass Index | 3 | 2022 | 2274 | 0.140 |
Why?
| | Virulence | 3 | 2008 | 255 | 0.140 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 168 | 0.130 |
Why?
| | Risk | 2 | 2020 | 855 | 0.130 |
Why?
| | Bariatric Surgery | 1 | 2020 | 196 | 0.130 |
Why?
| | Blood Pressure | 2 | 2022 | 1736 | 0.130 |
Why?
| | Obesity, Morbid | 1 | 2020 | 241 | 0.130 |
Why?
| | Mortality | 1 | 2018 | 307 | 0.120 |
Why?
| | Refugees | 1 | 2016 | 68 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1365 | 0.120 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2021 | 467 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 300 | 0.120 |
Why?
| | Family Health | 1 | 2016 | 198 | 0.120 |
Why?
| | Spouses | 1 | 2016 | 101 | 0.120 |
Why?
| | Mutation Rate | 1 | 2015 | 25 | 0.120 |
Why?
| | Genotype | 1 | 2020 | 1833 | 0.120 |
Why?
| | Physicians | 1 | 2023 | 866 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 756 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2008 | 323 | 0.110 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 122 | 0.110 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 520 | 0.110 |
Why?
| | Medication Adherence | 1 | 2019 | 558 | 0.110 |
Why?
| | Prognosis | 2 | 2019 | 3774 | 0.110 |
Why?
| | Exome | 1 | 2015 | 221 | 0.110 |
Why?
| | Tuberculosis | 2 | 2008 | 273 | 0.100 |
Why?
| | Age Factors | 1 | 2019 | 3152 | 0.090 |
Why?
| | Telemedicine | 1 | 2020 | 792 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1071 | 0.090 |
Why?
| | Young Adult | 4 | 2021 | 12455 | 0.090 |
Why?
| | Sample Size | 2 | 2022 | 116 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2739 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2021 | 10219 | 0.080 |
Why?
| | Mycobacterium marinum | 1 | 2008 | 3 | 0.080 |
Why?
| | United States Department of Veterans Affairs | 2 | 2024 | 623 | 0.070 |
Why?
| | Operon | 1 | 2008 | 64 | 0.070 |
Why?
| | Gene Frequency | 2 | 2022 | 502 | 0.070 |
Why?
| | Time Factors | 1 | 2019 | 6555 | 0.070 |
Why?
| | Lysosomes | 1 | 2008 | 137 | 0.070 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2008 | 33 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3628 | 0.070 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2020 | 92 | 0.070 |
Why?
| | Cohort Studies | 3 | 2023 | 5426 | 0.070 |
Why?
| | Toll-Like Receptors | 1 | 2008 | 179 | 0.070 |
Why?
| | Listeria monocytogenes | 1 | 2008 | 123 | 0.070 |
Why?
| | Phagocytosis | 1 | 2008 | 362 | 0.070 |
Why?
| | Transcriptional Activation | 1 | 2008 | 367 | 0.060 |
Why?
| | Genetic Loci | 2 | 2020 | 275 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2008 | 265 | 0.060 |
Why?
| | Glucose | 2 | 2021 | 1002 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2008 | 5455 | 0.060 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1418 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1207 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1843 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3075 | 0.050 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2008 | 353 | 0.050 |
Why?
| | Clonal Evolution | 1 | 2023 | 40 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2024 | 150 | 0.050 |
Why?
| | Hematopoiesis | 1 | 2023 | 184 | 0.050 |
Why?
| | Prospective Studies | 2 | 2024 | 7135 | 0.050 |
Why?
| | Skilled Nursing Facilities | 1 | 2023 | 130 | 0.050 |
Why?
| | Linkage Disequilibrium | 1 | 2022 | 257 | 0.050 |
Why?
| | Europe | 1 | 2022 | 363 | 0.050 |
Why?
| | United Kingdom | 1 | 2022 | 257 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2022 | 97 | 0.050 |
Why?
| | Albuminuria | 1 | 2022 | 183 | 0.040 |
Why?
| | Haplotypes | 1 | 2022 | 475 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 618 | 0.040 |
Why?
| | Fee-for-Service Plans | 1 | 2021 | 87 | 0.040 |
Why?
| | Mice | 5 | 2008 | 16961 | 0.040 |
Why?
| | Genome, Human | 1 | 2022 | 394 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 358 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 205 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2023 | 712 | 0.040 |
Why?
| | Decision Trees | 1 | 2018 | 90 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2542 | 0.040 |
Why?
| | Medicare | 1 | 2023 | 708 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2022 | 712 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 503 | 0.040 |
Why?
| | Genomics | 1 | 2022 | 718 | 0.040 |
Why?
| | Exercise Test | 1 | 2021 | 613 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 605 | 0.040 |
Why?
| | Patient Discharge | 1 | 2023 | 836 | 0.030 |
Why?
| | Odds Ratio | 1 | 2019 | 1019 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 869 | 0.030 |
Why?
| | Massachusetts | 1 | 2016 | 159 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2016 | 88 | 0.030 |
Why?
| | Animals | 5 | 2008 | 35391 | 0.030 |
Why?
| | Introns | 1 | 2016 | 251 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 31 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 176 | 0.030 |
Why?
| | Cells, Cultured | 3 | 2008 | 4084 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2016 | 353 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 2057 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1198 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1592 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 1986 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1875 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 362 | 0.030 |
Why?
| | Mutation | 1 | 2023 | 3717 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 20412 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3080 | 0.020 |
Why?
| | Mass Screening | 1 | 2019 | 1190 | 0.020 |
Why?
| | Islets of Langerhans | 1 | 2016 | 789 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7052 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2016 | 973 | 0.020 |
Why?
| | Registries | 1 | 2016 | 1899 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6417 | 0.020 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2008 | 19 | 0.020 |
Why?
| | Caspase 1 | 1 | 2008 | 143 | 0.020 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2008 | 44 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2008 | 148 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2008 | 182 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2008 | 189 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2008 | 97 | 0.020 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2008 | 149 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 190 | 0.020 |
Why?
| | Interleukin-18 | 1 | 2008 | 237 | 0.020 |
Why?
| | Hemolysis | 1 | 2008 | 199 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3968 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2008 | 372 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2005 | 63 | 0.020 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 56 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2005 | 110 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2005 | 157 | 0.010 |
Why?
| | Antigens, Bacterial | 1 | 2005 | 119 | 0.010 |
Why?
| | Multigene Family | 1 | 2005 | 199 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 745 | 0.010 |
Why?
| | Conserved Sequence | 1 | 2003 | 227 | 0.010 |
Why?
| | Plasmids | 1 | 2003 | 359 | 0.010 |
Why?
| | Calcium | 1 | 2008 | 1212 | 0.010 |
Why?
| | Protein Transport | 1 | 2003 | 429 | 0.010 |
Why?
| | Child | 1 | 2021 | 20884 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2005 | 2057 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 327 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2008 | 2881 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1687 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2835 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2750 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1724 | 0.010 |
Why?
| | Signal Transduction | 1 | 2008 | 4931 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2003 | 4078 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|